By Fineline Cube Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive commercialization rights to pumecitinib nasal spray (G‑011) in Greater China (mainland China, Hong Kong, Macau, and Taiwan). The deal includes up to RMB 100 million (USD 14.4 million) in consideration and a double‑digit promotion service fee post‑launch.
Deal Structure & Strategic Terms
| Item | Detail |
|---|---|
| Licensor | PrimeGenX Therapeutics Co., Ltd. |
| Licensee | Jumpcan Pharmaceutical (600566.SH) |
| Asset | Pumecitinib nasal spray (G‑011) |
| Indication | Allergic rhinitis |
| Territory | Greater China (exclusive) |
| Consideration | RMB 100 million (RMB 40 M upfront + RMB 60 M milestone) |
| Promotion Fee | Double‑digit sales‑based service fee post‑launch |
| Clinical Status | Phase III clinical study; trial nod in China (August 2023) |
| Innovation | Potential world’s first JAK inhibitor nasal spray |
Drug Profile & Clinical Development
- Mechanism: JAK1/2 inhibitor targeting inflammatory pathways in allergic rhinitis
- Formulation: Nasal spray delivery offers localized treatment with reduced systemic exposure
- Development: Phase III trial underway following Chinese regulatory approval in August 2023
- Market Need: Allergic rhinitis affects ~250 million : patients in China; limited options beyond antihistamines and intranasal steroids
- First‑in‑Class Potential: If approved, would be the first JAK inhibitor nasal spray globally
Market Impact & Commercial Outlook
- China Allergic Rhinitis Market: Valued at ¥15 billion : (~US$2.1 billion) in 2025, growing at 10% CAGR :
- Revenue Potential: Analysts project ¥500–800 million : (US$70–112 million) peak annual sales if pumecitinib captures 5–8% of moderate‑to‑severe patient segment
- Strategic Value: Partnership combines PrimeGenX’s innovation with Jumpcan’s commercial reach; double‑digit promotion fee aligns incentives for successful launch
- Competitive Landscape: Competes with fluticasone, mometasone steroids and azelastine antihistamines; JAK inhibition offers novel mechanism for refractory patients
- Next Steps: Phase III data readout expected Q3 2026; NDA submission targeted for H1 2027
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for pumecitinib nasal spray. Actual results may differ due to clinical trial outcomes, competitive dynamics, and NMPA review processes.-Fineline Info & Tech